Categories: BiotechClinicalStageOphthalmologyTherapeuticsVisionCare
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.07.2026 | Series B | $330M | - |
Mentions in press and media 6
| Date | Title | Description |
| 01.07.2026 | Ollin Biosciences Announces $330 Million Series B |
AUSTIN, TX, Ollin Biosciences, a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, announced an oversubscribed $330 million Series B financing.
>> Click here for more funding data on Ollin Bi... |
| 24.06.2026 | Ollin Biosciences Raises $330M in Series B Funding | Ollin Biosciences, Inc., an Austin, TX-based clinical-stage biotech advancing therapies for vision-threatening diseases, raised $330M in Series B funding.
The round was co-led by new investor TCGX and ARCH Venture Partners, with participati... |
| 31.03.2026 | Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edem... | OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimab
New anatomic data demonstrates OLN... |
| 09.01.2026 | Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema an... | SAN FRANCISCO and SUZHOU, China, Jan. 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for ... |
| 18.09.2025 | Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2) | SAN FRANCISCO and SUZHOU, China, Sept. 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines fo... |
| - | Ollin Biosciences | “Accelerating Next Generation Therapies for Ophthalmology” |
Reviews 0
